• Search

Human iPSC-Derived Ventricular Cardiomyocytes (Male)

Payment Options

We accept Visa and MasterCard in our online store.

Worldwide Shipping

We can get your purchases to you wherever you are.

Customer Care

As an Axol customer you have access to our support team and product specialists.

Description

Human iPSC-Derived Ventricular Cardiomyocytes (1 million cells)

The induced pluripotent stem cells (iPSCs) used to generate Human iPSC-Derived Ventricular Cardiomyocytes (male, ax2520) have been well characterized and used widely within the research community. For iPSC characterization information please see ‘Baghbaderani BA, Tian X, Neo BH, et al. cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications. Stem Cell Reports (2015)’. 

CD34+ cord blood cells were reprogrammed using episomal vectors under current good manufacturing practice (cGMP) conditions to produce a master bank of iPSCs. A non-GMP, research grade working bank of iPSCs were created from the master stock of cGMP-grade iPSCs for research studies (Baghbaderani et al., 2015). Axol has differentiated these matching research grade iPSCs into ventricular cardiomyocytes, as such these Human iPSC-Derived Ventricular Cardiomyocytes can be used for pre-clinical applications.



Product Specification

Starting material Cord blood CD34+ cells
Donor gender Male
Donor age at sampling Newborn
Reprogramming method Episomal vector
Genetic modification None
Size 1 million cells
Growth properties Adherent
Shipping conditions Dry ice
Storage conditions vapour phase nitrogen

Frequently Asked Questions

Yes, please follow the link here: https://www.axolbio.com/page/how-to-mea-atrial-and-ventricular-cardiomyocytes

ax2502 is derived from a female 42 year-old donor's PBMCs and Sendai virus reprogramming is used for generating its parental iPSC line. ax2505 is derived from CD34+ cord blood cells (male) that were reprogrammed using episomal vectors. These iPSCs have been used to generate ax0015 (iPSC-derived Neural Stem Cells), ax2115 (iPSC-derived Renal Proximal Tubular Cells) and ax0055 (iPSC-derived Sensory Neuron Progenitors). ax2520 is derived from CD34+ cord blood cells (male) that were reprogrammed using episomal vectors under current good manufacturing practice (cGMP) conditions. From the master stock of cGMP iPSCs a non-GMP, research grade working bank of iPSCs was created. Axol has then differentiated these research grade iPSCs into ventricular cardiomyocytes, this means that these cells are ideal for pre-clinical research as the iPSCs from cGMP are available for future clinical work. Please see publication below for information on this line of iPSCs: Baghbaderani BA, Tian X, Neo BH, et al. cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications. Stem Cell Reports (2015)

1. At the resuspension step, using P1000 and 1ml of plating medium to pipette up and down at least 5 times gently against the falcon tube which would partially disintegrate the aggregates; 2. In the counting step do not count the large aggregates and seed the culture vessel at a density of 50,000 cells/cm2 as instructed by the protocol; 3. The day after plating (Day 1), change Plating Medium to Cardiomocyte Maintenance Medium which would remove debris and cells that didn't attach (including large aggregates). 4. Using the recommended seeding density we have achieved over 70% confluence culture after plating.

No, you may passage within 3 days of plating to change culture vessel, but this is not recommended.

No, because the extra freeze/thaw cycle would effect the viability of the cells.

Beat rates may vary depending on the plating density. Please culture your ventricular cardiomyocytes to 100% confluence (when cardiac syncytium is formed) before assessing the beat rate.

Technical Resources

References

  • Shen Y, Dana H, Abdelfattah A.S et al., A genetically encoded Ca2+ indicator based on circularly permutated sea anemone red fluorescent protein Biorxiv (2018)
  • Sutton K, Ridly J, El Haou S et al., Human Stem Cell-Derived Cardiomyocytes: In Vitro Assays and Screening Platforms for Exploring Ventricular and Atrial Phenotypes Journal of Pharmacological and Toxicological Methods (2017)
  • Liquid Crystalline Networks toward Regenerative Medicine and Tissue Repair
  • Papp R, Bett GCL, Lis A et al., Genomic upregulation of cardiac Cav1.2α and NCX1 by estrogen in women. BioMed Central (2017)
  • Zuppinger C, Gibbons G, Dutta-Passecker P et al., Characterization of cytoskeleton features and maturation status of cultured human iPSC-derived cardiomyocytes. European Journal of Histochemistry (2017)
  • Chang Y, Broyles CN, Brook FA et al., Non-invasive phenotyping and drug testing in single cardiomyocytes or beta-cells by calcium imaging and optogenetics. PLoS One (2017)